BioSpace News Archive

Healthcare workers who interact with COVID-19 patients have a higher risk of becoming infected: Recent data shows that up to one in five are testing positive for the disease

MYOS RENS Technology Inc. (“MYOS” or “the Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, will announce financial results for the first quarter of 2020 on Friday, May 8, 2020 at 11:30 AM ET .

Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announced today it will report results for the first quarter ended March 31, 2020 on Monday, May 11, 2020 after market close. The

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GTX-102 for the treatment of Angelman syndrome (AS). GTX-102 is an investigational antisense oligonucleotide cur

New Delivery for Antibiotics Arms Medicine in the Fight against Antibiotic Resistance and COVID-19

SDM Northcoast is very excited to announce that it has added Dave Keiser as a Senior Research Analyst. Dave has nearly 20 years experience in healthcare research with 16 years experience in equity research, more than half of which focused on the dental industry at Northcoast Research and FTN Midwest

CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”), plans to release its results for the quarter ended March 31, 2020 , on Tuesday, May 12, 2020 after market close. The Company’s executive management will discuss the results during a conference call on Wednesday, May 13, 2020 at 8:30 am

Myst Therapeutics (Myst), a preclinical stage biotechnology company focused on developing selected TIL-based autologous T cell (PuriT™) therapy products for cancer, announced the appointment of George Smith, PhD, MBA as Vice President of Business Operations. Dr. Smith, who brings to Myst over 20 years of successful drug development experience at both biotechnology and global pharmaceutical companies, was previously the founder

Eve & Co Incorporated is pleased to announce that Health Canada has approved an amendment to the licence of its wholly-owned subsidiary, Natural MedCo Ltd., permitting the use of a 7,300 square foot area as eleven additional processing rooms.

Krystal Biotech reported financial results and key operational progress updates for the first quarter ending March 31, 2020.